Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders.
Cue Biopharma stock last closed at $0.26, up 3.53% from the previous day, and has decreased 73.49% in one year. It has underperformed other stocks in the Biotechnology industry by 0.39 percentage points. Cue Biopharma stock is currently +14.78% from its 52-week low of $0.23, and -74.86% from its 52-week high of $1.05.
As of Mar 25, 2026, there are 97.66M shares of CUE outstanding. The market cap of CUE is $25.78M. In the last 24 hours, 654,000 CUE shares were traded.
You need an online brokerage account to access the NASDAQ market and buy CUE shares.
Based on our analysis, eToro is the best place to buy stocks. Here's why:
Get $10 towards your purchase of stock by opening an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've selected your brokerage, it's time to fill out some personal details so you can invest in CUE stock today.
Now that you've created your account on stock apps to use, you need to deposit funds:
Check out this video walkthrough if you need help transferring funds into your new brokerage account.
Once you have selected the best place to buy Cue Biopharma stock, it's important to analyze their stock before you invest, so you truly wrap your head around the risk as well as the upside.
WallStreetZen was created to help everyday investors perform more accurate fundamental analysis quickly.
You can see all of the due diligence checks on CUE's stock page.
Investors use many financial metrics, analyses, models, and charts to gauge CUE's fair value.
Using relative valuations methods:
You can do more valuation research on CUE's stock here.
You can dive deeper into what analysts are forecasting on the Cue Biopharma stock forecast page.
Last year, CUE revenue was $27.47M. During the past five year, CUE's revenue has grown by 54.16% per year. This was faster than the Biotechnology industry average of 28.39%.
Find out more about CUE's earnings and revenue performance here.
Over the last 12 months, insiders at CUE have bought more shares than they have sold.
Pasha Sarraf, Director of CUE, was the latest CUE insider to buy. They bought $1,306.76 worth of CUE stock on Dec 30, 2025.
Research more about who owns CUE shares here.
No, Cue Biopharma doesn't provide an income stream by paying out dividends.
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
There are two primary order types:
Press the Open Trade button and eToro will place the order.
If you need more help with investing in stocks on eToro, watch the how to video below:
Now that you own some shares in CUE, you'll want to stay up-to-date on your new stock purchase.
Start a watchlist to keep track of your CUE stock.
To reiterate, here are the 6 steps to buy stock in Cue Biopharma:
If you are looking for a brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you want to monitor your new investment in Cue Biopharma, hit the button below to create your watchlist.